ArticleScientific reports2025
Anti-cancer Effects of 1,4-Dialkoxynaphthalene-Imidazolium Salt Derivatives through ERK5 kinase activity inhibition.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Gastrodin Inhibits Bacterial Biofilm Formation, Thereby Activating the Antibacterial Activity of Antibiotics.Molecules (Basel, Switzerland) · 2026Article
- The Discovery of Small ERK5 Inhibitors via Structure-Based Virtual Screening, Biological Evaluation and MD Simulations.Molecules (Basel, Switzerland) · 2025Article
- New Anticancer Agents: Design, Synthesis and Evaluation.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ERK5 has emerged as a promising therapeutic target in cancer treatment due to its pivotal role in regulating tumor cell proliferation and survival. In this study, we synthesized novel derivatives of 1,4-dialkoxynaphthalene-2-acyl or 2-alkyl-imidazolium salt (NAIMS), assessed their binding affinity with the ERK5 protein through molecular modeling, and evaluated their anti-cancer activity through the ERK5 kinase assay. Based on the MTT assay and qRT-PCR analysis of 21 synthesized NAIMS, the IC
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.